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Association of Selected Antipsychotic Agents With Major Adverse
Cardiovascular Events and Noncardiovascular Mortality in Elderly
Persons
Marie Sahlberg, MD; Ellen Holm, MD;* Gunnar H. Gislason, MD, PhD; Lars Køber, MD, Dsc; Christian Torp-Pedersen, MD, DSc;
Charlotte Andersson, MD, PhD*
Background-—Data from observational studies have raised concerns about the safety of treatment with antipsychotic agents (APs)
in elderly patients with dementia, but this area has been insufﬁciently investigated. We performed a head-to-head comparison of
the risk of major adverse cardiovascular events and noncardiovascular mortality associated with individual APs (ziprasidone,
olanzapine, risperidone, quetiapine, levomepromazine, chlorprothixen, ﬂupentixol, and haloperidol) in Danish treatment-na€ıve
patients aged ≥70 years.
Methods and Results-—We followed all treatment-na€ıve Danish citizens aged ≥70 years that initiated treatment with APs for the
ﬁrst time between 1997 and 2011 (n=91 774, mean age 827 years, 35 474 [39%] were men). Incidence rate ratios associated
with use of different APs were assessed by multivariable time-dependent Poisson regression models. For the ﬁrst 30 days of
treatment, compared with risperidone, incidence rate ratios of major adverse cardiovascular events were higher with use of
levomepromazine (3.80, 95% CI 3.43 to 4.21) and haloperidol (1.85, 95% CI 1.67 to 2.05) and lower for treatment with ﬂupentixol
(0.54, 95% CI 0.45 to 0.66), ziprasidone (0.31, 95% CI 0.10 to 0.97), chlorprothixen (0.76, 95% CI 0.61 to 0.95), and quetiapine
(0.68, 95% CI 0.58 to 0.80). Relationships were generally similar for long-term treatment. The majority of agents were associated
with higher risks among patients with cardiovascular disease compared with patients without cardiovascular disease (P for
interaction <0.0001). Similar results were observed for noncardiovascular mortality, although differences in associations between
patients with and without cardiovascular disease were small.
Conclusions-—Our study suggested some diversity in risks associated with individual APs but no systematic difference between
ﬁrst- and second-generation APs. Randomized placebo-controlled studies are warranted to conﬁrm our ﬁndings and to identify the
safest agents. ( J Am Heart Assoc. 2015;4:e001666 doi: 10.1161/JAHA.114.001666)
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T he estimated worldwide prevalence of dementia was35.6 million in 2010 and is expected to almost double
within the next 20 years.1 Dementia may be accompanied by
physical aggression, anxiety, hallucinations, and behavioral
problems, which are referred to as behavioral and psycho-
logical symptoms of dementia.2 For management of these
symptoms, antipsychotic agents (APs) are frequently pre-
scribed.3,4 Because the second-generation APs are consid-
ered to have fewer side effects than ﬁrst-generation APs, they
are now more widely used in patients with behavioral and
psychological symptoms of dementia than ﬁrst-generation
APs.5,6 In recent years, however, data from observational
studies have raised concerns about the safety of this
practice.7–11 Of particular note, it has been suggested that
the risk of sudden cardiac death associated with second-
generation APs may be at least as high as that for ﬁrst-
generation APs.12 Moreover, use of APs in people with
dementia has been associated with increased risk of stroke
and acute myocardial infarction, but prior studies did not
differentiate between ﬁrst- and second-generation APs.13,14
In addition to using APs to treat behavioral problems in
elderly patients with dementia, elderly persons without
From the Department of Geriatric Medicine, Aalborg University Hospital, Aalborg,
Denmark (M.S.); Department of Geriatric Medicine, Nykøbing Falster Hospital,
Nykøbing Falster, Denmark (E.H.); Faculty of Health and Medical Sciences,
University of Copenhagen, Denmark (E.H., G.H.G., L.K.); Department of Cardiol-
ogy, Gentofte Hospital, Hellerup, Denmark (G.H.G., C.A.); National Institute of
Public Health, University of Southern Denmark, Copenhagen, Denmark (G.H.G.);
The Heart Centre, Rigshospitalet, Copenhagen, Denmark (L.K.); Institute of
Health, Science and Technology, Aalborg University, Aalborg, Denmark (C.T.-P.).
*Dr Holm and Dr Andersson contributed equally to the present work.
Correspondence to: Marie Sahlberg, MD, Department of Geriatric Medicine,
Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark. E-mail:
m.i.e.sahlberg@gmail.com
Received November 30, 2014; accepted July 16, 2015.
ª 2015 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.114.001666 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on June 1, 2016http://jaha.ahajournals.org/Downloaded from 
dementia are often prescribed APs for conditions such as
anxiety, depression, or insomnia; however, the outcomes
associated with AP use in this particular group have not been
well investigated, and it is not known if risks differ for patients
with and without dementia. Moreover, several APs are
considered to pose greater risk of adverse outcomes for
patients with established cardiovascular disease (CVD) than
for patients without CVD, but head-to-head comparisons of
individual APs in patients with and without CVD are sparse.15
To further address these issues, we investigated the risk of
major adverse cardiovascular events (MACE) and noncardio-
vascular mortality associated with individual APs in a Danish
population with and without diagnosed dementia and with and
without CVD.
Methods
The study was approved by the Danish Data Protection
Agency (2007-58-0015/local j.nr. GEH-2014-012 I-Suite nr:
02720). Register-based studies in which persons cannot be
identiﬁed do not need ethics approval in Denmark. All Danish
citizens are medically covered by a tax-ﬁnanced system that
provides each citizen with equal health care free of copay-
ment. For administrative purposes, the government has kept
records of all hospitalizations (in-hospital and outpatient
visits) since 1978 (in the Danish National Patient Registry)
and records of all prescription claims from Danish pharmacies
since 1995 (in the Danish Register of Medicinal Product
Statistics). Furthermore, registration of all births and deaths,
including dates of occurrence, has been complete for all
citizens since 1968 (in the National Population Register).
Because all Danish citizens are given a permanent personal
civil registration number at time of birth or immigration, they
can be followed up by individual-level linkage of the registers.
Population and Comorbidities
For the present study, we included all persons in Denmark
between 1997 and 2011 who were aged ≥70 years at the
time when they claimed their ﬁrst prescription of antipsy-
chotic medication and who had previously been treatment-
na€ıve (ie, allowing for a look back to 1995, when the Danish
Register of Medicinal Product Statistics was established). We
identiﬁed comorbidities throughout the whole observational
period by continuous screening of the Danish National Patient
Register. Because most diagnoses were for chronic condi-
tions, people were classiﬁed as having the disease from the
ﬁrst day of diagnosis. For all diagnoses but dementia,
schizophrenia, and Parkinson’s disease, only validated in-
hospital diagnoses were considered.16 In addition to previ-
ously validated chronic comorbid diagnoses, we retrieved
information on acute delirium based on in-hospital diagnoses.
Because the diagnoses of dementia, Parkinson’s disease, and
schizophrenia are often based on outpatient visits, diagnoses
from both in-hospital and outpatient visits were considered for
these comorbidities.
Outcomes
The primary outcomes were MACE, comprising the ﬁrst
occurring nonfatal acute myocardial infarction (International
Classiﬁcation of Diseases, 10th revision [ICD-10] code I21) or
nonfatal ischemic stroke (ICD-10 codes I63 and I64 [“I64”
denotes unspeciﬁed stroke, of which the majority are of
ischemic origin])17 and cardiovascular mortality (ICD-10 codes
I00 to I99) and non–cardiovascular-related mortality (causes
of mortality were obtained from the Danish Causes of Death
Register).
Pharmacotherapy
From the National Register of Medicinal Product Statistics, we
identiﬁed exposure to the individual APs outlined in Table 1.
For these agents and for vitamin K antagonists (B01AA03),
clopidogrel (B01AC04), low-dose aspirin (B01AC06), and loop
diuretics (C03CA01, C03CA02), treatment was updated
continuously, that is, patients were considered to be exposed
only while covered by claimed prescriptions. To determine
treatment length and average daily dosages, up to 3
consecutive prescriptions were considered in a retrospective
manner. We created an algorithm for each agent in which
minimum, maximum, and typical daily dosages of used
medication were deﬁned. For patients’ ﬁrst claimed prescrip-
tions, the typical daily dosage was assigned, and treatment
length was calculated by dividing the amount of claimed
medications by that daily dosage. For patients who were
covered by a previous prescription at the time of claiming a
new prescription, the daily dosage was reset, and a new daily
dosage was calculated as the amount of claimed medications
during the previous period divided by time between prescrip-
tion claims (based on up to 3 previous prescriptions without
treatment breaks). If calculated dosages exceeded the
predeﬁned highest daily dosages, patients were assigned
the maximum dosages, and exceeding tablets were assumed
to be stored and consumed during the immediate period
following the end of the last prescription.
For other medications (ie, dementia medications [ATC code
N06DA], beta blockers [C07], thiazides [C03A], calcium
channel blockers [C08], digoxin [C01AA], renin-angiotensin
system inhibitors [C09], aldosterone blockers [C03D], and
statins [C10AA]), treatment status was updated every
30 days for the whole observational period. Persons were
considered to be in treatment with the different medications if
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they claimed at least 1 prescription during the preceding
4 months (this pragmatic method was applied because of
computational limitations).
Statistics
All patients were followed from the date of ﬁrst claimed
prescription until date of death, emigration, or December 31,
2011. The incidence rate ratios (IRRs) associated with
exposure to APs were analyzed using multivariable Poisson
regression models. The following variables were included as
time-dependent variables: treatment with antipsychotic med-
ications; all comorbidities (schizophrenia, Parkinson’s disease,
dementia, acute delirium, prior cerebrovascular disease, heart
failure, acute myocardial infarction, peripheral vascular dis-
ease, chronic obstructive pulmonary disease, atrial ﬁbrillation,
moderate or severe renal disease, diabetes, cancer, and
cancer with metastases; for ICD-10 codes, see Table 2); age;
and use of warfarin, aspirin, clopidogrel, loop diuretics,
thiazides, renin-angiotensin system blockers, aldosterone
antagonists, statins, beta blockers, calcium channel blockers,
or digoxin. All models were adjusted for the aforementioned
variables and for actual calendar year and sex. Use of
antipsychotic medications was included as a time-dependent
multilevel categorical variable for which people using >1
medication for a given time were grouped in a separate use of
multiple medication category. People who were not covered by
a claimed prescription were assigned to a no treatment
category. For all comparisons, use of risperidone as
monotherapy served as the referent group (because this
group was the largest quantitatively). We performed 2
separate types of analyses. In the ﬁrst, we created 3 different
categorical variables for antipsychotic use according to time
elapsed since ﬁrst treatment because time dependency for
risks was present (P for interaction between time elapsed and
associated risks <0.0001; use of medications was split into
the ﬁrst 30 days, 31 to 365 days, and >365 days after
treatment initiation). After having explored the IRRs among
different medications in different time periods, the differences
appeared to be rather small between the periods; therefore, in
subsequent models, we included a variable reﬂecting only
Table 1. Classiﬁcation of the Different Antipsychotic Agents
Name ATC Code Generation
Chlorprothixen N05AF03 First
Flupentixol N05AF01 First
Haloperidol N05AD01 First
Levomepromazine N05AA02 First
Olanzapine N05AH03 Second
Risperidone N05AX08 Second
Quetiapine N05AH04 Second
Ziprasidone N05AE04 Second
Table 2. ICD-10 Codes for Various Medical Conditions
Condition ICD-10
Dementia F00, F01, F02, F03, F05.1, G30
Schizophrenia F20
Parkinson’s disease G20
Acute delirium F05
Ischemic heart disease I20, I23, I24, I25
Cerebrovascular disease I60 to I69, G45, G46
Acute myocardial infarction I21, I22, I23
Heart failure I50, I42, I110, I13.0, I13.2
Atrial fibrillation I48
Peripheral artery disease I70 to I74
Chronic obstructive pulmonary disease J40 to 47, J60 to 67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
Cancer C00 to C75, C81 to 96
Metastases C76 to C80
Renal disease N00 to 06, N07, N11, N17 to 19, R34, I12, I13, Q61
Diabetes Treatment with glucose-lowering medication (ATC code A10)
ICD-10 indicates International Classiﬁcation of Diseases, 10th Revision.
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time since ﬁrst treatment initiation to account for time
dependency in risks. In the second models, we tested for
effect modiﬁcation between the different treatment groups
and prevalent dementia (diagnosis or use of dementia
medications) and CVD (myocardial infarction, congestive
heart failure, stroke, or peripheral vascular disease) by
inclusion of an interaction term between the categorical
treatment variable and CVD or dementia, respectively.
Because these were highly signiﬁcant, we created a categor-
ical dummy variable stratifying use of medications by the
prevalence of the different diseases. All analyses were done in
SAS version 9.4 (SAS Institute). A 2-sided P<0.05 was
considered statistically signiﬁcant.
Results
We identiﬁed 91 774 persons (mean age 827 years,
35 474 [39%] were men). Numbers of those ever exposed
to the different APs are presented in Table 3, along with the
baseline characteristics for different exposure groups. The
different exposure groups had comparable age, sex, and
comorbidity burdens, although patients receiving levomepro-
Table 3. Baseline Characteristics of Study Population
Haloperidol
(n=20 873)
Flupentixol
(n=10 807)
Levopromazine
(n=16 127)
Chlorprothixen
(n=7762)
Quetiapine
(n=12 854)
Risperidone
(n=28 161)
Olanzapine
(n=16 102)
Ziprasidone
(n=500)
Age, y (SD) 83 (7) 79 (6) 80 (7) 79 (7) 82 (6) 84 (7) 82 (7) 81 (7)
Sex, male (%) 9122 (44) 3081 (29) 7105 (44) 2843 (37) 5149 (40) 10 268 (36) 5589 (35) 170 (34)
Cerebrovascular disease (%) 5193 (25) 2544 (24) 3266 (20) 1647 (21) 3338 (26) 7241 (26) 4050 (25) 123 (25)
Heart failure (%) 3378 (16) 1763 (16) 3227 (20) 1203 (16) 1554 (12) 4064 (14) 2357 (15) 76 (15)
Acute myocardial infarction (%) 1837 (9) 1091 (10) 1557 (10) 680 (9) 995 (8) 2144 (8) 1203 (7) 32 (6)
Peripheral arterial disease (%) 1428 (7) 705 (7) 1336 (8) 529 (7) 660 (5) 1460 (5) 818 (5) 24 (5)
Chronic obstructive pulmonary
disease (%)
2737 (13) 1822 (17) 4369 (27) 1381 (18) 1377 (11) 2855 (10) 1795 (11) 51 (10)
Cancer (%) 6097 (29) 2072 (19) 4826 (30) 1447 (19) 1731 (13) 3292 (12) 2344 (15) 48 (10)
Cancer with metastases (%) 1948 (9) 384 (4) 1348 (8) 238 (3) 199 (2) 416 (1) 452 (3) 5 (1)
Atrial fibrillation (%) 3432 (15) 768 (7) 1860 (11) 750 (9) 1799 (13) 1065 (4) 1866 (12) 50 (10)
Parkinson’s disease (%) 483 (2) 298 (3) 335 (2) 197 (3) 1516 (12) 889 (3) 1050 (7) 15 (3)
Acute delirium (%) 1357 (7) 212 (2) 210 (1) 175 (2) 902 (7) 1473 (5) 720 (4) 15 (3)
Schizophrenia (%) 71 (0.3) 25 (0.2) 45 (0.3) 60 (1) 128 (1) 287 (1) 288 (2) 15 (3)
Diabetes (%) 2226 (11) 785 (7) 1552 (10) 720 (9) 1309 (10) 2728 (10) 1435 (9) 45 (9)
Renal disease (%) 1044 (5) 501 (5) 854 (5) 409 (5) 525 (4) 1073 (4) 689 (4) 23 (5)
Dementia diagnosis (%) 1638 (8) 154 (1) 374 (2) 235 (3) 2394 (19) 3357 (12) 1718 (11) 83 (17)
Treatment with dementia medications
(%)
3058 (15) 813 (8) 903 (6) 669 (9) 4625 (36) 6688 (24) 3550 (22) 163 (33)
Statin treatment (%) 2051 (10) 939 (9) 1194 (7) 977 (13) 2057 (16) 2488 (9) 1224 (8) 44 (9)
RAS inhibitors (%) 3832 (18) 1945 (18) 2811 (17) 1604 (21) 2801 (22) 4869 (17) 2426 (15) 68 (14)
Calcium channel blockers (%) 3095 (15) 1816 (17) 2589 (16) 1277 (16) 1908 (15) 3862 (14) 2104 (13) 73 (15)
Beta blockers (%) 3411 (16) 1673 (15) 2098 (13) 1185 (15) 2242 (17) 4256 (15) 2125 (13) 57 (11)
Digoxin (%) 2839 (14) 869 (8) 2117 (13) 608 (8) 1146 (9) 3231 (11) 1699 (11) 38 (8)
Thiazides (%) 3445 (17) 1929 (18) 2596 (16) 1286 (17) 2283 (18) 4715 (17) 2642 (16) 86 (17)
Aldosterone blockers (%) 1269 (6) 361 (3) 1224 (8) 259 (3) 546 (4) 1326 (5) 699 (4) 17 (3)
Aspirin (%) 6874 (33) 2850 (26) 4525 (28) 2187 (28) 4678 (36) 9746 (35) 5151 (32) 168 (34)
Clopidogrel (%) 355 (2) 86 (1) 152 (1) 100 (1) 286 (2) 370 (1) 186 (1) 2 (0.4)
Warfarin (%) 834 (4) 286 (3) 538 (3) 256 (3) 557 (4) 994 (4) 471 (3) 13 (3)
Baseline characteristics for different antipsychotic medication users. Numbers are presented as counts (%) for discrete variables and means (SD) for continuous variables. Characteristics
were obtained at ﬁrst day of treatment; thus groups are not exclusive. RAS indicates renin-angiotensin system.
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mazine and haloperidol had higher prevalence of cancers
(30% versus 10% for the other groups).
Total exposure time, MACE, and noncardiovascular mortality
for each treatment group are given in Tables 4 and 5. Crude
event rates were lowest for ﬂupentixol and chlorprothixen
compared with the other AP groups. As seen in the tables, for all
agents, we observed a highly increased incidence rate of MACE
and noncardiovascular mortality during the ﬁrst month after
initiation, with a subsequent decline for longer treatment
durations. Associated adjusted IRRs were increased for treat-
ment with levomepromazine or haloperidol and treatment with
multiple medications, whereas treatment with ﬂupentixol,
ziprasidone, chlorprothixen, or quetiapine was associated with
a signiﬁcantly lower IRR compared with treatment with
risperidone, as shown in Figure 1 (MACE) and Figure 2
(noncardiovascular mortality). For longer treatment duration,
levomepromazine and use of multiple medications were no
longer associated with increased risks compared with risperi-
done monotherapy (Figures 1C and 2C). The risks associated
with use of different antipsychotic medications differed for
Table 4. Numbers of Major Adverse Cardiovascular Events,
Exposure Time, and Crude Incidence Rates for Different
Antipsychotic Agents
Events/Person-
Years
Unadjusted Incidence Rate
(Per 100 Person-Years)
Associated risks for the first 30 days after initiation
Risperidone 842/1765 47.7 (44.6 to 51.0)
Flupentixol 142/859 16.5 (14.0 to 19.5)
Chlorprothixen 132/460 28.7 (24.2 to 34.0)
Levomepromazine 1162/717 162 (153 to 172)
Haloperidol 1250/1340 93.3 (88.3 to 98.6)
Ziprasidone 3/30 10.1 (3.2 to 31.2)
Quetiapine 284/952 29.8 (26.5 to 33.5)
Olanzapine 428/1106 38.7 (35.2 to 42.5)
Multiple medications 143/142 101 (85 to 119)
Associated risks for the first 31 to 365 days after initiation
Risperidone 2294/10 523 21.8 (20.9 to 22.7)
Flupentixol 397/3577 11.1 (10.1 to 12.2)
Chlorprothixen 168/1466 11.5 (9.9 to 13.3)
Levomepromazine 426/2179 19.5 (17.8 to 21.5)
Haloperidol 1471/3834 38.4 (36.5 to 40.4)
Ziprasidone 3/16 19.3 (6.2 to 59.9)
Quetiapine 925/6234 14.8 (13.9 to 15.8)
Olanzapine 1151/6645 17.3 (16.3 to 18.4)
Multiple medications 172/621 27.7 (23.9 to 32.2)
Associated risks for the first >365 days after initiation
Risperidone 2516/16 231 15.5 (14.9 to 16.1)
Flupentixol 488/5676 5.6 (7.9 to 9.4)
Chlorprothixen 288/3350 8.6 (7.7 to 9.6)
Levomepromazine 515/4603 11.2 (10.3 to 12.2)
Haloperidol 602/2908 20.7 (19.1 to 22.4)
Ziprasidone 31/265 11.7 (8.2 to 16.6)
Quetiapine 1001/8995 11.1 (10.5 to 11.8)
Olanzapine 1635/13 032 12.5 (12.0 to 13.2)
Multiple medications 130/1086 12.0 (10.1 to 14.2)
Table 5. Numbers of Noncardiovascular Mortality, Exposure
Time, and Crude Incidence Rates for Different Antipsychotic
Agents
Events/Person-
Years
Unadjusted Incidence Rate
(Per 100 Person-Years)
Associated risks for the first 30 days after initiation
Risperidone 630/1809 34.8 (32.2 to 37.7)
Flupentixol 99/867 11.4 (9.4 to 13.9)
Chlorprothixen 116/469 24.8 (20.6 to 29.7)
Levomepromazine 2052/750 274 (262 to 286)
Haloperidol 2365/1411 168 (161 to 175)
Ziprasidone 12/31 39.1 (22.2 to 68.8)
Quetiapine 281/982 28.6 (25.5 to 32.2)
Olanzapine 472/1136 41.6 (38.0 to 45.5)
Multiple medications 239/148 162 (143 to 184)
Associated risks for the first 31 to 365 days after initiation
Risperidone 1900/10 949 17.4 (16.6 to 18.2)
Flupentixol 293/3671 8.0 (7.1 to 9.0)
Chlorprothixen 122/1506 8.1 (6.8 to 9.7)
Levomepromazine 580/2292 25.3 (23.3 to 27.4)
Haloperidol 2109/4254 49.6 (47.5 to 51.7)
Ziprasidone 3/18 16.8 (5.4 to 52.0)
Quetiapine 1009/6552 15.4 (14.5 to 16.4)
Olanzapine 1064/6896 15.4 (14.5 to 16.4)
Multiple medications 236/656 36.0 (31.7 to 40.9)
Associated risks for the first >365 days after initiation
Risperidone 2704/17 604 15.4 (14.8 to 16.0)
Flupentixol 339/6098 5.6 (5.0 to 6.2)
Chlorprothixen 226/3605 6.3 (5.5 to 7.1)
Levomepromazine 481/4992 9.6 (8.8 to 10.5)
Haloperidol 568/3167 18.0 (16.5 to 19.5)
Ziprasidone 49/284 17.3 (13.0 to 22.8)
Quetiapine 1631/9916 16.4 (15.7 to 17.3)
Olanzapine 1850/14 275 13.0 (12.4 to 13.6)
Multiple medications 185/1165 15.9 (13.8 to 18.3)
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Figure 1. Multivariable-adjusted risks of MACE for different treatment regimens in different time
periods after treatment initiation: (A) ﬁrst 30 days, (B) 31 to 365 days, (C) >365 days. MACE
indicates major adverse cardiovascular events.
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Figure 2. Multivariable-adjusted risks of noncardiovascular mortality for different treatment
regimens in different time periods after treatment initiation: (A) ﬁrst 30 days, (B) 31 to
365 days, (C) >365 days.
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patientswith andwithout CVD andwere greater among patients
with established CVD (P for interaction between treatment
group and CVD <0.00001) (Figure 3). Similarly, the risks were
slightly higher among patients without established dementia
compared with patients with dementia (P for interaction
between treatment group and dementia <0.0001) (Figure 4).
Discussion
In this Danish study of all persons without prior use of APs who
were aged ≥70 years, we investigated the association between
different APs and risks of MACE and noncardiovascular
mortality. In general, we observed that use of haloperidol or
levomepromazine and treatment with multiple medications
were associated with similar or greater IRRs than use of
risperidone, whereas treatment with ﬂupentixol, ziprasidone,
chlorprothixen, or quetiapine was associated with signiﬁcantly
lower IRRs compared with treatment with risperidone. The
absolute event rates were highest shortly after treatment
initiation and declined with long-term use.
Safety of APs in Elderly Persons
After ﬁndings of increased risk of cerebrovascular events
associated with use of second-generation APs,10,18,19 the US
Food and Drug Administration (FDA) issued a warning in 2005
A
B
Figure 3. Multivariable-adjusted risks of (A) MACE and (B) noncardiovascular mortality stratiﬁed by
prevalent CVD. CV indicates cardiovascular; CVD, cardiovascular disease; MACE, major adverse
cardiovascular events.
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against use of second-generationAPs in dementia.18,20 In 2008,
the FDA extended this warning to include use of ﬁrst-generation
APs in dementia.21 Several studies have since demonstrated
increased mortality with use of APs in dementia,8,10,22 and
some studies have shown increasedmortality in elderly patients
regardless of dementia status.9,11,19 Previous studies have also
suggested that the use of APs is associated with increased risk
of myocardial infarction among older patients with treated
dementia13 and that exposure to APs may be a trigger for
stroke.11 Furthermore, a Cochrane review estimated the risk of
cerebrovascular events to be >3-fold higher in risperidone-
versus placebo-treated elderly patients with dementia.23 Our
observations suggest that medications belonging to the
second- and ﬁrst-generation classes of APs may be associated
with more or less comparable risk in elderly patients with or
without dementia, although ﬂupentixol, chlorprothixen, and
quetiapine may be particularly associated with lower MACE and
mortality rates than risperidone.
For all drugs, we found that the incidence rates of MACE
and noncardiovascular mortality were highest during the ﬁrst
A
B
Figure 4. Multivariable-adjusted risks of (A) MACE and (B) noncardiovascular mortality stratiﬁed by
prevalent dementia. CV indicates cardiovascular; MACE, major adverse cardiovascular events.
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30 days of treatment and declined with longer exposure time.
This ﬁnding is consistent with the ﬁndings of other stud-
ies.11,22,24 When elderly patients are prescribed APs, it may
be due to neuropsychiatric symptoms in dementia or to
delirium as part of a somatic disease that carries a high
mortality risk. Because we were unable to accurately control
for several diseases in our study, it cannot be excluded that
the higher risks observed, especially among nondemented
elderly people who were treated, may be partly due to
confounding by indication. Delirium, however, is an acute
disease with high short-term mortality; therefore, associations
with long-term use may be less prone to confounding than the
analyses of short-term use. Worth emphasizing in this context
is that the relative risk of mortality with levomepromazine and
haloperidol shortly after treatment initiation was higher than
that observed for other APs. A very high proportion of patients
using these drugs had diagnosed cancer; therefore, we cannot
rule out that the IRR for the ﬁrst period after treatment
initiation was driven by confounding by indication. Even when
excluding patients with a preexisting cancer, haloperidol has
been shown to be associated with the highest risk of death
among APs users in nursing homes.24
First- Versus Second-Generation APs
Second-generation APs have been promoted for having a low
risk of extrapyramidal symptoms compared with ﬁrst-
generation APs. Previous studies suggest that both ﬁrst-
and second-generation APs can lower blood pressure, leading
to increased risk of falls and to a varying extent to prolonged
QT interval, which might lead to arrhythmia and death.25–28
Another problem related to second-generation APs is adverse
inﬂuence on glucose metabolism, diabetes, and blood lipid
composition, leading to increased cardiovascular risks with
long-term use.29,30
Several prior observational studies have compared the
safety of ﬁrst- versus second-generation APs6,8,9,11,19,22,31–33
and generally have indicated that the risk of death and/or
MACE when using second-generation APs is at least as high
as that for ﬁrst-generation APs.21 At least 1 retrospective
cohort study has suggested that in older adults with
dementia, second- and ﬁrst-generation APs were associated
with comparable risks of ischemic stroke.31 A larger retro-
spective cohort study in 2009 also suggested a comparable
dose-related increased risk of sudden cardiac death for ﬁrst-
and second-generation APs.12
Strengths and Limitations of the Study
The main strength and novelty of this study is that we
compared MACE and noncardiovascular mortality risk among
individual APs across the ﬁrst and second generations in a
rather large group of patients aged ≥70 years. Moreover,
because medical care is offered to all Danish citizens without
copayment and because medications are reimbursed by the
government, selection bias related to socioeconomic status
and, for example, prior participation in the labor market is
likely less pronounced compared with many other observa-
tional studies. Another strength of our study was the sample
size, which allowed us to examine the effect of individual
drugs, although it must be acknowledged that we might still
have lacked power to ﬁrmly conclude anything about some of
the individual drugs (particularly ziprasidone). Some limita-
tions, however, merit consideration. We lacked data on
several clinical variables including blood pressure, hemato-
logical proﬁles, electrocardiograms, and indication for treat-
ment. All of these variables may have inﬂuenced clinicians’
decisions of whether to prescribe a particular agent. Our data
must be interpreted with great caution, bearing these
limitations in mind.
Conclusion and Clinical Implications
There is an important but limited role for antipsychotic
treatment of severe neuropsychiatric symptoms.23 Our study
demonstrated high incidence rates of MACE and noncardio-
vascular mortality associated with use of individual APs in
elderly persons with or without dementia and with and
without CVD. This underscores that APs should be used with
caution in elderly patients, regardless of dementia status, at
the lowest possible dose and for shortest possible time. A
particular focus on risks and beneﬁts is warranted among
people with prevalent CVD because these patients seem to
have the highest risks associated with APs. Our study further
suggested some diversity in risks associated with individual
APs but no systematic differences between ﬁrst- and second-
generation APs. Randomized placebo-controlled studies are
warranted to conﬁrm our ﬁndings and to identify the safest
agents. Until then, the antipsychotic beneﬁt in people with
and without dementia must be considered against the risks of
adverse events. Finally, in Denmark, restrictions on the use of
APs are focused predominantly on people with dementia. Our
study warrants a broader focus on elderly people in general.
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